Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. develops and commercializes nitric oxide-based medical device and biopharmaceutical programs. Its recurring news centers on LungFit PH, a tankless inhaled nitric oxide system that uses Plasma Pulse Technology to generate nitric oxide from room air, and on commercial access through hospital purchasing channels.
Company updates also cover nitric oxide programs for respiratory indications, including severe lung infections, and Beyond Cancer's ultra-high concentration nitric oxide, or UNO, platform for investigational solid-tumor immunotherapy. Additional recurring themes include clinical data presentations, scientific publications, intellectual property, leadership changes, investor conferences, and governance matters.
Beyond Air (NASDAQ: XAIR) entered financing agreements with Streeterville Capital providing up to $32 million in potential proceeds: a $12 million promissory note and a $20 million equity line of credit (ELOC). Pro forma cash, cash equivalents, restricted cash and marketable securities totaled $22.9 million as of September 30, 2025, which includes the $12 million note. The promissory note bears 15% annual interest, matures in 24 months with no payments for the first 12 months, and places $6 million in a restricted account. The ELOC allows sale of up to $20 million of common stock over 24 months and requires an S-1 resale registration. Management says the financing extends runway into calendar 2027 and supports LungFit PH commercial expansion and a planned second-generation launch before end of 2026.
Beyond Air (NASDAQ: XAIR) will release second fiscal quarter 2026 financial results for the period ended September 30, 2025 on Monday, November 10, 2025. The company's management will host a conference call and webcast the same day at 4:30 PM Eastern Time to discuss results.
Dial-in details: Domestic 1-877-407-0784, International 1-201-689-8560, Conference ID 13756730. A live webcast will be available in the Events section of the company's website, and an online replay will be posted about one hour after the call.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference. The event will take place on October 9, 2025, in New York, NY.
The company's Chief Financial Officer, Douglas Larson, will be available for one-on-one meetings with investors during the conference. Interested investors can schedule meetings through their Roth Capital Partners representatives.
Beyond Air (NASDAQ: XAIR) has secured approximately $3.25 million in gross proceeds through the exercise of existing warrants. The agreement involves the immediate exercise of warrants to purchase 1,439,126 shares of common stock at a reduced price of $2.21 per share.
As part of the transaction, the company will issue new unregistered warrants to purchase up to 719,561 shares of common stock at $0.0625 per warrant. These new warrants will have an exercise price of $2.21 per share, with immediate exercisability and a five-year term. The proceeds will support Beyond Air's clinical and pre-clinical programs, operating expenses, and working capital.
NeuroNOS, a subsidiary of Beyond Air (NASDAQ: XAIR), has received FDA Orphan Drug Designation (ODD) for its lead therapy BA-101 in treating Glioblastoma (GBM), an aggressive brain cancer. This marks the company's second ODD and its entry into oncology.
GBM currently has limited treatment options with median survival less than 12 months, and survival rates of less than 20% at two years and less than 10% at five years. The ODD grants several benefits, including seven years of market exclusivity, tax credits for clinical trials, and prescription drug user fee waivers.
The company's approach focuses on NO inhibition strategy, supported by research showing nitric oxide as an important modulator in GBM treatment response.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York.
Chairman and CEO Steve Lisi will represent the company, with an on-demand presentation webcast available starting September 5, 2025, at 7:00 a.m. ET. Management will also be available for one-on-one investor meetings during the conference.
Beyond Air (NASDAQ: XAIR) has expanded its global distribution network for LungFit PH, a medical device that generates nitric oxide from ambient air. The company has signed new distribution agreements in Japan, South Korea, Costa Rica, Guatemala, Panama, and El Salvador, bringing its total international coverage to 34 countries with a combined population of 2.7 billion people.
In Japan, Beyond Air partnered with AMCO Incorporated, a leading medical device distributor with over 70 years of experience. The LungFit PH system eliminates the need for traditional high-pressure cylinders, offering a more efficient and environmentally friendly solution for hospital settings. Hospital tender submissions are currently in progress in several regions while awaiting regulatory approvals in others.
Beyond Air (NASDAQ: XAIR) reported strong fiscal Q1 2026 results, with revenue surging 157% to $1.8 million compared to $0.7 million in the same period last year. The company secured a significant national group purchasing agreement with Premier, Inc., gaining access to over 4,350 member hospitals and health systems.
The company reaffirmed its FY2026 revenue guidance of $12-16 million. LungFit PH's commercial expansion continues globally, now reaching over 30 countries. Beyond Air reported a net loss of $7.7 million ($1.53 per share) and cash position of $6.5 million as of June 30, 2025. The company recently completed a 1-for-20 reverse stock split to maintain Nasdaq compliance.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, has scheduled its first fiscal quarter 2026 financial results conference call for Tuesday, August 12, 2025, at 4:30 PM ET.
The company will discuss its financial performance for the quarter ended June 30, 2025. Investors can access the conference call through domestic (1-877-407-0784) or international (1-201-689-8560) dial-in numbers using conference ID 13754769. A webcast will be available through the company's website, with a replay accessible after the call.
Beyond Air (NASDAQ: XAIR) has secured a national group purchasing agreement with Premier, Inc., effective July 15th, 2025. The agreement enables Premier's network of healthcare providers to access special pricing for Beyond Air's LungFit PH system and disposable NO2 Smart Filters.
The LungFit PH platform utilizes patented Ionizer™ technology to generate unlimited, on-demand nitric oxide from ambient air for ventilator delivery. The system operates on minimal power, equivalent to a 60-watt lightbulb, and includes Smart Filters that provide 12 hours of uninterrupted therapy. Premier serves two-thirds of U.S. healthcare providers, making this agreement significant for Beyond Air's market reach.